Giancarlo Agnelli

Giancarlo Agnelli led the CARAVAGGIO trial, the landmark randomized study demonstrating that oral apixaban is non-inferior to subcutaneous dalteparin for cancer-associated VTE treatment without increased risk of major bleeding, including in gastrointestinal cancers. This trial changed clinical practice by providing level 1 evidence for DOAC use in cancer-associated thrombosis. He has contributed extensively to understanding anticoagulant safety in cancer patients. His clinical research has been pivotal in modernizing VTE treatment for cancer patients.